An update from Tryptamine Therapeutics ( (AU:TYP) ) is now available.
Tryptamine Therapeutics Limited announced that all resolutions were passed at their recent General Meeting, indicating strong shareholder support. The company is advancing its clinical trials with promising results in treating various conditions using their novel psilocin formulations, which could enhance their market position and offer new therapeutic options for patients with unmet medical needs.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing proprietary formulations of psilocin for use in combination with psychotherapy to treat diseases with unmet medical needs. Their lead product, TRP-8803, is an innovative IV-infused psilocin formulation designed to improve the efficacy and safety of psilocybin treatments. The company has conducted successful Phase 2a clinical trials for conditions such as binge eating disorder and fibromyalgia, and is exploring treatments for irritable bowel syndrome.
YTD Price Performance: -10.0%
Average Trading Volume: 1,701,475
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$48.5M
For an in-depth examination of TYP stock, go to TipRanks’ Stock Analysis page.